Medicare and Medicaid Together: Can Dual-Eligibles Use the GLP-1 Bridge?

Yes, in most cases. If you’re dually eligible for Medicare and Medicaid, you can use the Medicare GLP-1 Bridge as long as you’re enrolled in a qualifying Medicare drug plan and you meet the program’s clinical rules. CMS has confirmed that dually-eligible beneficiaries in eligible plan types who satisfy the prior-authorization criteria can access Bridge medications. The Bridge runs through your Medicare drug coverage, not through Medicaid, which actually simplifies things, because state-by-state Medicaid weight-loss rules don’t decide your access here. A few details determine whether you’re in, so let’s walk through them.

The plan-type requirement is the first gate

The Bridge isn’t open to every Medicare enrollee. To qualify, you have to be in a standalone Part D prescription drug plan or a Medicare Advantage plan that includes drug coverage (an MA-PD). For dual-eligibles, that usually describes your setup already, since most receive their drug coverage through one of those plan types, frequently a Dual Eligible Special Needs Plan. CMS has specified that beneficiaries in Special Needs Plans are eligible to participate.

If you happen to get coverage through one of the arrangements CMS excluded, the picture changes, but for the typical dual-eligible enrolled in a qualifying drug plan, this gate is one you’ve already cleared.

Why Medicaid’s rules don’t decide this

Here’s the part that relieves a lot of anxiety. Whether your state Medicaid program covers GLP-1s for weight loss has been a coin flip, with only a minority of states doing so. Dual-eligibles in non-covering states have often been stuck. The Bridge sidesteps that, because it’s a Medicare demonstration. Your access flows from your Medicare drug plan and the federal program’s rules, not from your state’s preferred drug list.

The clinical rules still apply to you

Dual-eligibility gets you in the door, but it doesn’t waive the medical criteria. The Bridge requires that you need the medication for weight management, and your prescriber must attest that you don’t have type 2 diabetes, moderate-to-severe sleep apnea, or MASH, since those would route you to standard coverage instead. You’ll also need to meet the program’s weight and health thresholds, which combine a body mass index requirement with qualifying conditions such as high blood pressure or chronic kidney disease.

Consider a scenario where someone has both Medicare and Medicaid, lives in a state whose Medicaid has never covered weight-loss drugs, and has a BMI in the qualifying range with hypertension but no diabetes. Under the old rules, her state’s exclusion left her paying full cash price or going without. Through the Bridge, her dual status and qualifying plan let her access Wegovy for $50 a month, regardless of what her state Medicaid does or doesn’t cover.

What you’ll actually pay

Eligible beneficiaries, dual-eligible included, pay the flat $50 monthly copay. Keep one wrinkle in mind: because the Bridge sits outside Part D, that $50 doesn’t draw on the low-income subsidy and doesn’t count toward your deductible or out-of-pocket cap. For many dual-eligibles accustomed to very low or zero cost-sharing through Extra Help, $50 may be more than your usual copay on other drugs, so it’s worth confirming the number before you start.

The medications behind the program

The drugs you’d access are the same fully studied products available everywhere else. Semaglutide’s trial record is extensive; PIONEER 1, for instance, showed that oral semaglutide as a first-line monotherapy significantly lowered HbA1c versus placebo in adults with type 2 diabetes managed by diet and exercise alone. The Bridge changes how you pay for these medications, not what they are.

If the Bridge isn’t a fit, or you want another option

The Bridge has firm edges. You need the right plan type, you have to clear the clinical attestation, and the program is set to end after 2027. If you fall outside those lines or want a path that doesn’t depend on Medicare program rules, a cash-pay telehealth option is worth a look.

TrimRx connects you with licensed providers who prescribe semaglutide or tirzepatide when it’s clinically appropriate, and it bundles the provider visit and shipping into a flat monthly structure with no insurance required, with program pricing from $179 to $1,579 depending on the medication and plan. To see whether a personalized plan fits your circumstances, the free assessment quiz is a simple first step.

This article is for general educational purposes and is not medical or financial advice. Eligibility, dual-coverage rules, and program details change and vary by individual circumstance. Confirm current details with CMS, your plan, your state Medicaid program, and a licensed provider before making decisions.